Definitive Healthcare (NASDAQ:DH) Releases Q3 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its third quarter 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.040-0.050 for the period, compared to the consensus earnings per share estimate of 0.040. The company issued revenue guidance of $54.0 million-$55.0 million, compared to the consensus revenue estimate of $55.5 million. Definitive Healthcare also updated its FY 2026 guidance to 0.180-0.200 EPS.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DH. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. Bank of America reaffirmed an “underperform” rating and issued a $0.70 price objective on shares of Definitive Healthcare in a research note on Monday, June 29th. Robert W. Baird set a $1.10 target price on Definitive Healthcare in a research report on Friday, May 8th. Finally, Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Definitive Healthcare presently has a consensus rating of “Reduce” and a consensus price target of $1.88.

Definitive Healthcare Price Performance

Shares of NASDAQ DH traded down $0.01 during mid-day trading on Monday, hitting $0.70. 400,591 shares of the company’s stock traded hands, compared to its average volume of 358,377. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.35. The company’s 50-day moving average is $0.78 and its two-hundred day moving average is $1.12. The company has a market capitalization of $73.71 million, a P/E ratio of -0.43, a PEG ratio of 11.51 and a beta of 1.35.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $55.93 million during the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%. On average, equities analysts anticipate that Definitive Healthcare will post 0.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several institutional investors have recently made changes to their positions in the company. Boothbay Fund Management LLC bought a new position in Definitive Healthcare during the 4th quarter valued at about $92,000. Jain Global LLC bought a new stake in Definitive Healthcare in the fourth quarter worth about $75,000. PharVision Advisers LLC purchased a new position in shares of Definitive Healthcare during the third quarter valued at approximately $120,000. BNP Paribas Financial Markets boosted its position in shares of Definitive Healthcare by 32.9% during the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after buying an additional 4,407 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Definitive Healthcare during the third quarter valued at approximately $155,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.